Tafasitamab Plus Revlimid Granted FDA Priority Review for Relapsed or Refractory DLBCL
News
The U.S. Food and Drug Administration (FDA) has granted priority review to MorphoSys’ application seeking approval of its CD19 antibody tafasitamab, in combination with Revlimid (lenalidomide), to treat people with relapsed ... Read more